Chronic cough

Chronic cough—not such a heartsink

A H Morice

Knowledge of the pathophysiology of the different conditions which cause chronic cough is vital to achieving a correct diagnosis and successful treatment.

Patients present with symptoms. Doctors are trained to recognise disease. There is no better illustration of these two different paradigms than cough. Unfortunately for the patient, the sensory input triggering the cough reflex may arise from anywhere in the territory of the vagus nerve. Thus, chronic cough may be caused by conditions treated by at least three different specialists—the ENT surgeon, the gastroenterologist, and the chest physician. Because of our speciality led view of the world, the doctor may not have received training in the condition causing the symptom. There is a risk of treating the patient for the condition with which the doctor is familiar rather than that most likely to be the cause of the cough. In a recent survey of over 300 patients who had asked for information about chronic cough, most had consulted at least one specialist of whom 69% were chest physicians. Presumably the treatment had not worked, which is why they needed further information: this suggests an urgent need for greater understanding. For this reason, Thorax has commissioned a review series on the aetiology and treatment of this disabling and socially isolating symptom.

In contrast to experience in general chest clinics, there is extensive literature to support the very high treatment success rates seen in specialist cough clinics throughout the world, supporting grounds for optimism. Most of these therapeutic successes are achieved without resorting to sophisticated specialised investigations. The clinical history is the major clue to the diagnosis in chronic cough. However, knowledge of the pathophysiology of the various conditions is vital to understanding these clues. In the differentiation of asthmatic and reflux cough, for example, the diurnal variability of the cough is often sufficient to make the diagnosis. In 1698 Sir John Floyer first described the still unexplained nocturnal exacerbations of asthma symptoms, and nocturnal cough remains a common symptom of cough predominant asthma. In contrast, a patient with reflux cough will rarely cough at night. Appreciation of this requires a knowledge of the physiology of the lower oesophageal sphincter. The sphincter closes at night, diminishing reflux and causing the cough to abate. The patient with reflux cough wakes peacefully and not as in Floyer’s own graphic description of the morning exacerbation “at first waking the fit takes me”. Rather, the paroxysms of coughing start when the patient gets up and the sphincter opens to allow for belching. It is hoped that this series of reviews will provide the reader with valuable clinical pointers to aid in the management of these potentially challenging patients.

In the last two reviews of the series, recent developments in the physiology and pharmacology of cough will be summarised. For many years the term “cough receptor” has been used in what is no more than the description of the type of nerve fibre transmitting the stimulus. In the last few years the first genuine cough receptor—the VR1—has been cloned, and there has been a rapid increase in the basic knowledge of cough receptor function. From this may arise treatments which may be effective in the single most common presenting complaint for which new...
developed societies. The provision of ICU beds in the UK has historically been one of the smallest in the industrialised world. Only 2.6% of hospital beds were designated for intensive care before 2001 compared with averages of 3.3% and 5–7% in Europe and North America, respectively. Furthermore, in the UK the practice of intensive care medicine was led principally by clinicians with anaesthesia as their base speciality, who were being asked increasingly to provide multiple services within the medical and allied professions—most notably the Intensive Care Society—together with central government recognised that a new multidisciplinary approach to the delivery of critical care services across acute hospitals was desirable. Consequently, in April 1999 the Department of Health appointed a review body tasked with developing a framework for the future organisation and delivery of critical care. The group published its report, “Comprehensive Critical Care”, in 2000. It acknowledged that many of the difficulties faced were both organisational and structural. A number of seminal recommendations emerged, the principal one being that a new approach based upon severity of illness should be used to determine the delivery of service in accordance with the individual needs of the patient, rather than their physical location (table 1). It was agreed that the provision of comprehensive critical care should be defined by a systemically planned and delivered service integrated into a hospital-wide approach, extending beyond the physical boundaries of the intensive care and high dependency units. Networks were to be established between NHS trusts, working to common standards and protocols within geographically defined regions. It was recognised that a planned approach to workforce development was needed, balancing the skill mix between medical, nursing, and allied health professionals such that the most appropriate mix of skills could be brought to bear on specific clinical problems. Finally, the service was to incorporate a culture based on data collection, thereby promoting evidence based clinical care.

Two other relevant reports have since focused attention on the standards of care delivered to acutely ill patients within medical wards. The first was commissioned by the Royal College of Physicians following the publication of data indicating that the care of severely ill medical inpatients in the UK is frequently suboptimal, implicating poor recognition of the severity of illness by junior clinical staff, a lack of senior medical input, and the slow or inappropriate application of therapeutic interventions. Indeed, one investigation of the quality of medical management prior to ICU admission found it to be unsatisfactory in 54% of cases. Mortality in this group was significantly higher than in those managed appropriately in the pre-ICU phase (48% vs 25%). Even more disturbingly, studies of events leading to “unexpected” in-hospital cardiac arrest have indicated that many patients have evidence of marked physiological deterioration clearly recorded before the event without appropriate action being taken. A key requirement for the increased provision of non-invasive ventilatory (NIV) support services was identified in the report, together with a number of other points relating particularly to the identification of acutely ill patients and the inadequacies of training junior clinical staff.

The second report, by the National Confidential Enquiry into Perioperative Deaths (NCIPOD), has commissioned an investigation of the care of medical patients requiring or developing level 3 dependency. Although the results are still awaited, they are likely to reinforce the impression that suboptimal management of medical inpatients in UK hospitals is not uncommon.

What has been the impact of these reports on the availability of facilities for patients with increased dependency?

More specifically, are there implications for respiratory physicians?

How should a journal such as Thorax recognise the importance of these developments?

### IMPACT ON AVAILABILITY OF FACILITIES

ICU capacity in the winter of 2000 underwent a marked expansion in England with an increase of approximately 22% in total bed numbers catering for patients with what is now termed level 2 and level 3 dependency. Level 2 bed numbers increased by approximately 50% and level 3 beds by 8%. This is clearly good news for the critically ill, but issues relating to improved organisation and staffing remain to be addressed. Nevertheless, the Department of Health has recognised the deficiencies in the training of junior medical staff by recommending that all trainees, whatever their intended speciality, should be exposed to a period of training in intensive care medicine.

Thoracic medicine has a key part to play in the delivery of a comprehensive critical care service within all acute trusts. This was recognised implicitly in the report of the Royal College of Physicians Working Group and developed further by the NHS Modernisation Agency subgroup emanating from the expert group producing “Comprehensive Critical Care”. Their recently published report suggested that an NIV service should be established in each acute trust, on the grounds that selected groups of patients with acute respiratory insufficiency have been shown to benefit from this intervention. Equally importantly, it may be more suited to patients’ needs and can reduce the complication rate attributable to endotracheal intubation. The development of such a service would not only facilitate the movement of patients from level 3 to level 2 dependency, but would also afford a more palatable and dignified means of providing respiratory support to those who have little hope of being successfully weaned from mechanical ventilation owing to the chronicity and/ or terminal nature of their pulmonary disease. It was also recognised that NIV should be provided in specialist centres for patients with delayed weaning and for those likely to require long term and domiciliary ventilatory support.

### Table 1 Classification of illness severity

| Level 0 | Patients whose needs can be met through normal ward care in an acute hospital |
| Level 1 | Patients at risk of their condition deteriorating, or those recently relocated from higher levels of care, whose needs can be met on an acute ward with additional advice and support from a specialist. |
| Level 2 | Patients requiring more detailed observations or intervention including support for a single failing organ system or postoperative care and those “stepping down” from higher levels of care. |
| Level 3 | Patients requiring advanced respiratory support alone or basic respiratory support together with support of at least two organ systems. This level includes all complex patients requiring support for multorgan failure |
IMPLICATIONS FOR RESPIRATORY PHYSICIANS

Respiratory physicians have diagnostic and therapeutic skills particularly relevant to the care of the acutely ill. Thus, respiratory insufficiency represents the most common cause of deterioration for patients likely to require level 3 support, and acute respiratory illnesses represent the second most common reason for Accident & Emergency consultation in the UK. Furthermore, respiratory physicians already make an enormous contribution to the provision of acute emergency care to patients arriving in acute trusts via the unselected medical take. Thoracic physicians also possess skills that are complementary to those of intensivists with predominantly anaesthetic backgrounds. In particular, they have the experience and resources to provide the often prolonged inpatient care that ICU survivors require once they no longer need the services of critical care. In addition, they are well placed to provide longer term outpatient care that ICU survivors require once they no longer need the services of intensive care medicine. In particular, thoracic physicians also possess skills that are particularly relevant to the care of the acutely ill. Thus, respiratory physicians have diagnostic and therapeutic skills particularly relevant to the care of the acutely ill. Therefore, respiratory physicians are well placed to provide longer term outpatient care that ICU survivors require once they no longer need the services of intensive care medicine. Furthermore, respiratory physicians could participate in the care of patients requiring prolonged weaning on the model of North American intermediate care units.

The recognition by the Specialist Advisory Committee for Training in Respiratory Medicine that gaining competency in certain skills relevant to intensive care medicine forms a crucial part of the training programme of all specialist registrars is tacit recognition of the increasingly close ties between respiratory medicine and critical care. Indeed, the recognition that one year of training in intensive care medicine (incorporating experience in anaesthesia) can substitute for an equivalent period in general internal medicine/respiratory medicine has precluded the need to extend the overall period of training for those seeking recognition of their experience at intermediate level by the Intercollegiate Board for Training in intensive care medicine. Specialty recognition, involving the award of a dual or even triple (general internal medicine, respiratory, intensive care medicine) certificate of specialty training, is now available for those prepared to add a further year to their training programme.

In other countries (notably North America) where the vast majority of intensive care facilities are staffed by individuals with training in pulmonary/critical care, intensive care and respiratory medicine have traditionally been closely linked. This pattern may be adopted increasingly across Europe following the publication of a report by the European Respiratory Society exploring the basis of this relationship. In summary, recognition that individuals with clinical experience gained in a variety of base specialties have a part to play in the delivery of newly designated critical care services should encourage the participation of respiratory physicians in this increasingly important activity. We would encourage some to become intensivists in their own right, but all should work within the multidisciplinary team to develop and expand the service within the spirit of “Comprehensive Critical Care”.

“The new editors of Thorax pledge to pay particular attention to submissions...”

IMPLICATIONS FOR JOURNALS IN RESPIRATORY MEDICINE

So what are the implications of the closer links developing between respiratory medicine and intensive care medicine for journals such as Thorax? We suggest that they are several.

Firstly, many of the key advances in critical care that have emerged in recent years have been related to the investigation and management of patients with acute and chronic respiratory insufficiency. Indeed, the American Thoracic Society’s decision in the early 1990s to change the title of the American Review of Respiratory Disease to incorporate critical care medicine is tacit recognition of the growing and increasingly influential scientific base of intensive care medicine. Secondly, it seems reasonable that respiratory physicians should be educated in subjects relevant to the acutely ill patient, especially if up to 6 months of experience for all specialist registrars is to take place within the environs of a critical care service. Moreover, if an increasing burden of responsibility for the provision of acute care, at least for patients with respiratory insufficiency, is to be placed upon our specialty, then the publication of appropriate scientific advances and allied educational initiatives—both features of this publication over the years—should be encouraged. Thirdly, while Thorax remains the journal of the British Thoracic Society, by encouraging submissions from individuals practising within intensive care medicine with non-respiratory base specialties, the breadth, interest and circulation of the journal and its impact on clinical practice will be augmented. Fourthly, recognition that acute illness will represent an ever escalating burden upon the NHS should lead investigators and scientists to address the problems of the critically ill with ever increasing urgency. Indeed, we suggest that relevance of research to the needs of stakeholders—the patients we serve—will become an issue of increasing importance to the research councils and charitable bodies in deciding on the allocation of their scarce resources. Finally, and possibly most important of all, intensive care medicine is exciting and very broad based. Legitimate areas of investigation range from genetic predisposition to critical illness through the cellular aspects of the pathophysiology of the inflammatory response (manifest in sepsis, the systemic inflammatory response syndrome, and their sequela) to complex economic and ethical issues.

We are privileged to report that the new editors of Thorax pledge to pay particular attention to submissions (scientific, clinical, and reviews) emerging from the fields of acute care and intensive care medicine. Not surprisingly, we applaud this initiative and hope that it leads to an expansion of the scientific and clinical base of a newly recognised specialty that will bring together multiple disciplines in a novel and exciting fashion.

Thorax 2003;58:829–832

References

A new hypothesis that considers the role of the immune system in the largely unexplored role of the immune system in the pathogenesis of COPD. If true, this hypothesis will generate new therapeutic opportunities in COPD. If true, this hypothesis will generate new therapeutic opportunities in COPD.

**THE CURRENT VIEW**

The Global initiative for the diagnosis, management, and prevention of Obstructive Lung Disease (GOLD) defines COPD as a “disease state which is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases”. Many studies have attempted to characterise this abnormal inflammatory response. However, this issue is far from resolved because the results of these studies vary according to the severity of the disease (mild, moderate, or severe), the type of controls studied (never smokers, smokers with normal lung function, patients with stable COPD compared with those studied during exacerbations of the disease), the compartment of the lung sampled (central airways, peripheral airways, alveolar space), and/or the bias of the study towards the role of a given cell type. A critical review of this literature indicates the following salient features: (1) all smokers develop airway inflammation; (2) this is amplified in patients with COPD, particularly during exacerbations of the disease; (3) there is a direct relationship between the severity of the disease and the intensity of the inflammatory response; (4) airspace inflammation persists after smoking cessation; (5) all inflammatory cell types (macrophages, neutrophils, lymphocytes, eosinophils, natural killer cells) are implicated in the inflammatory process of COPD; (6) many different mediators released by activated inflammatory cells can damage lung structures; and (7) oxidative stress due to cigarette smoking is important in the pathogenesis of COPD. How all these cells and inflammatory mediators interact and contribute to the disease is presently unclear. Yet, a better understanding of these interactions is mandatory if new therapeutic options are to be developed.

**THE QUESTIONS**

In this context, we believe that there are three specific questions of particular relevance.

**Why do only some smokers develop COPD?**

Tobacco smoking is the main risk factor for COPD, but not all smokers develop the disease. Although it is possible that more patients would develop COPD if they did not succumb from other smoking related conditions such as ischaemic heart disease and lung cancer, the fact remains that most smokers do not present with clinically significant airflow obstruction. If we accept that COPD is associated with an abnormal inflammatory response in the lungs, we should concede that excessive inflammation is the key to susceptibility. However, the mechanisms underlying this enhanced inflammatory response in susceptible smokers are completely unknown.

**Why does inflammation persist after quitting smoking?**

Although relatively small numbers of patients have been studied, several papers have shown that inflammation persists long after the patient has stopped smoking. The mechanism(s) underlying this observation are also unknown, but it clearly indicates the existence of some self-perpetuating pathogenic process, initiated but not necessarily perpetuated by smoking, that prevents the normal resolution of the inflammatory response. This type of mechanism seems to operate in many autoimmune diseases.

**What are the mechanisms of exacerbations of COPD?**

Patients with COPD often present with exacerbations during the course of their disease. These episodes significantly diminish their quality of life, may require admission to hospital, and cause significant mortality. They are characterised by increased airway inflammation, but evidence supporting the former can be found in only 50–60% of cases and the latter do not seem to be powerful enough to explain the majority of exacerbations. Thus, many of these episodes remain unexplained.

**LESSONS FROM AUTOIMMUNE DISEASES**

Autoimmune diseases are chronic inflammatory conditions characterised by the loss of tolerance to self-antigens or development of immunity to foreign epitopes that cross react with self-antigens. It is...
interesting to consider here that COPD shares many clinical and pathophysiological characteristics of several autoimmune diseases such as rheumatoid arthritis (RA). Firstly, smoking is a risk factor for both COPD and RA. Secondly, once initiated, the inflammatory response of RA is self-perpetuating. To some extent, this may be analogous to the continued airflow inflammation seen after cessation of smoking. Thirdly, exacerbations occur both in RA and COPD. Yet, while in COPD they are “explained” by external factors such as airway infection and air pollution, in RA they are considered an integral part of the disease process, characterised by T cells sensitised to either cartilage epitopes and/or degradation products of intestinal bacteria that mimic them, homing to the synovium and contributing to the maintenance—or amplification of the inflammatory process. Finally, similarities between the inflammatory cells (neutrophils, macrophages, T lymphocytes) and cytokines (tumour necrosis factor (TNF)-α, interleukin (IL)-6, IL-8) involved in the pathogenesis of RA and COPD are remarkable.

THE HYPOTHESIS

We propose that an acquired immune response to newly created or altered epitopes is an essential component in the pathogenesis of COPD. This hypothesis implies the loss of tolerance to self-epitopes and would qualify COPD as an “autoimmune” disease induced by cigarette smoking. If true, this hypothesis may help to answer the questions posed above—namely, why only some smokers develop the disease, why lung inflammation persists after smoking cessation and, perhaps, the underlying pathobiology of some exacerbations of COPD. To support this hypothesis we will review the evidence for alterations of the “normal” components of the immune response in COPD and propose several (testable) mechanisms by which autoimmunity may arise in a disease caused by a clearly identified external agent (tobacco smoking).

IMMUNE RESPONSES IN COPD

The normal immune response comprises the innate (natural) and acquired (adaptive) responses. The innate response involves phagocytic cells (neutrophils, macrophages), cells that release inflammatory mediators (mast cells, eosinophils), and natural killer cells. The acquired response requires the proliferation of B and T cells after antigen presentation by specialised cells (macrophages and dendritic cells). Many elements of both types of response are abnormal in COPD. Implicitly, although not explicitly, the innate immune response has long been considered as dominating the pathogenesis of COPD, since the traditional proteinase-antiproteinase theory of the pathogenesis of COPD requires the participation of neutrophils and macrophages, which are both prominent elements of such a response. However, the role of the acquired response has largely been ignored. Yet, there is some evidence to support the contention that there is increased acquired immunity in COPD: (1) both helper (CD4+) and cytotoxic T lymphocytes (CD8+) accumulate in the lung parenchyma of patients with COPD; (2) B lymphocytes form the core of the so-called bronchus-associated lymphoid tissue (BALT) which has been shown to be significantly increased in smokers and in patients with COPD; (3) smoking is associated with an expansion of the population of antigen presenting cells on the epithelial surface of the lower respiratory tract; and (4) preliminary data from our laboratory suggest an increased prevalence of viral antibody titres in smokers with COPD compared with smokers with normal lung function (unpublished data). Whether these abnormalities represent a response to smoking or play a pathogenic role in the development of COPD will have to be explored in future studies.

POTENTIAL MECHANISMS

An aberrant acquired immune response can result from either a defect in the selection, regulation or death of immune cells (T or B lymphocytes) or from the generation of new (self or foreign) antigens. Both possibilities could operate in COPD through several different mechanisms. Tobacco smoking (the main risk factor for COPD) modulates the proliferation and death pathways of lymphocytes, can generate new epitopes by either directly oxidising existing proteins or indirectly by interfering with the clearance of apoptotic cells, thus exposing anatomically sequestered intracellular antigens to the immune system, and upregulates the population of antigen presenting cells in the lungs thus amplifying the capacity to process new antigens. In addition, several factors frequently associated with COPD may also contribute to an acquired immune response. For instance, chronic airway bacterial colonisation is common in COPD. In RA intestinal bacteria have been shown to be a source of new antigens contributing to the maintenance of the inflammatory process. It is therefore possible that chronic airway colonisation by bacteria may exert a similar effect in COPD. Viral infections and oxidative stress created by environmental particles could also contribute to the development of new/altered epitopes. In summary, there are many different potential mechanisms that can theoretically boost an acquired immune response in COPD. The challenge is now to design the appropriate studies (human and experimental) to prove (or disprove) this hypothesis.

IMPLICATIONS

The current view is that chronic inflammation is a key pathogenic element in COPD because it contributes to the decline in lung function that characterises the disease. Available anti-inflammatory treatment (that is, inhaled steroids) does not have a consistent effect on the inflammation in COPD. New therapeutic strategies are therefore urgently needed. This is particularly important if the airspace inflammation in COPD continues despite quitting smoking. If true, the hypothesis proposed here should lead to the development of new therapeutic strategies aimed at immunomodulation. These may both halt the progression of the disease and prevent the episodes of exacerbation. If so, this would contribute enormously to improving the well being of patients with COPD and to decreasing the enormous healthcare burden associated with this disease.
ACKNOWLEDGEMENTS

The authors thank the Scottish weather for keeping Dr Agusti indoors and working on this hypothesis when he would otherwise be out enjoying the Festival. The authors also thank Drs Ian McNees and Robin Stevenson (Department of Medicine in Glasgow University) and Dr Sarah Howie (Department of Pathology in Edinburgh University) for helpful discussions over this hypothesis. ABEMAR and the Fundación Catalana de Neumología (FUCAP) supported the sabbatical leave of Dr Agusti at the University of Edinburgh during the summer of 2001. Ken Donaldson is the Transco British Lung Foundation Fellow in Air Pollution and Respiratory Health.

Thorax 2003;58:832–834

Authors’ affiliations
A Agusti, Servei de Pneumología, Hospital Universitari Son Dureta, Palma de Mallorca, Spain
W MacNee, K Donaldson, ELEGI Laboratory, University of Edinburgh, UK
M Cosio, McGill University, Montreal, Canada

Correspondence to: Professor W MacNee, ELEGI Coll Research Laboratory, Willie Building, University of Edinburgh Medical School, Teviot Place, Edinburgh EH89AG; wmacnee@ed.ac.uk

REFERENCES

1 Murray CCJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269–76.

www.thoraxjnl.com
Hypothesis: Does COPD have an autoimmune component?

A Agustí, W MacNee, K Donaldson and M Cosio

*Thorax* 2003 58: 832-834
doi: 10.1136/thorax.58.10.832

Updated information and services can be found at: [http://thorax.bmj.com/content/58/10/832](http://thorax.bmj.com/content/58/10/832)

These include:

**References**

This article cites 45 articles, 17 of which you can access for free at: [http://thorax.bmj.com/content/58/10/832#BIBL](http://thorax.bmj.com/content/58/10/832#BIBL)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Inflammation (1020)
- Health education (1223)
- Smoking (1037)
- Tobacco use (1039)
- Health effects of tobacco use (211)
- Epidemiologic studies (1829)
- Bronchitis (235)
- Health policy (183)
- Health service research (169)
- Ischaemic heart disease (122)
- Lung cancer (oncology) (670)
- Lung cancer (respiratory medicine) (670)
- Lung neoplasms (608)
- Smoking cessation (154)
- TB and other respiratory infections (1273)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)